A Study to Evaluating the Pharmacokinetics, Safety, and Efficacy of ATG 016 Monotherapy in IPSS-R Intermediate Risk and Above Myelodysplastic Syndrome (MDS)
Clinical trial NCT04691141 · TERMINATED
Trial details
- NCT number
- NCT04691141
- Sponsor
- Shanghai Antengene Corporation Limited
- Status
- TERMINATED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-02-23
- Primary completion
- 2023-09-19
- Enrollment
- 15
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.